Heart Disease & Cardiology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

This Phase III study is testing elecoglipron, a new medication, in adults with heart failure who have either preserved or mildly reduced heart pumping ability. The goal is to see if elecoglipron can lower serious heart-related problems compared to a placebo. The trial includes patients worldwide who are already receiving standard heart failure treatments, and it welcomes participants whether or not they have diabetes.

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

This Phase IV trial is exploring whether early use of finerenone, an oral drug, helps patients hospitalized with acute heart failure. It focuses on improving outcomes and reducing the chances of heart failure worsening while patients are still in the hospital. The study is taking place in Japan and plans to enroll about 550 patients with a specific level of heart function.

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

This Phase II study involves children with severe heart failure who need heart-lung support through a machine called Cardiohelp. Researchers are comparing two types of blood thinners to find safer and more effective treatments that could increase survival and reduce complications. The trial is recruiting in the United States and aims to enroll 50 children with serious heart conditions.

The Use of Artificial Intelligence-Enhanced Electrocardiograms in the Chest Pain Clinic to Risk Stratify Patients, Provide Rapid Reassurance and Enable a Low-Cost Clinical Pathway

This study is testing a new approach using artificial intelligence with electrocardiograms (heart rhythm tests) to help patients who come to chest pain clinics. The AI tool aims to quickly identify those at low risk, reducing unnecessary tests and providing faster reassurance. The trial will enroll 4,000 patients in the United Kingdom and will compare the costs and outcomes after one year.

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

This study looks at using AI-guided ultrasound screening to detect heart valve and structural heart problems early in older adults. Finding these issues sooner could lead to timely treatments and better heart health before symptoms appear. The trial plans to enroll 1,440 patients aged 65 and older at three sites in the United States over two years.

Heart disease research continues to explore new treatments and technologies aimed at improving diagnosis and care. This week's studies highlight advances in medications for heart failure, innovative support for children with severe cardiac conditions, and the use of artificial intelligence to speed diagnosis and improve patient management. These efforts may lead to better outcomes and more personalized care for people living with heart disease.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.